This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Project: Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: A Systematic Review for the U.S. Preventive Services Task Force [Entered Retrospectively]

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-7 Sara Grusing 1, 2, 3, 4, 5, 6, 7


Associated Studies (each link opens a new tab)

Title Author Year
Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region. Bottero J., Boyd A., Lemoine M., Carrat F., Gozlan J., Collignon A., Boo N., Dhotte P., Varsat B., Muller G., Cha O., Valin N., Nau J., Campa P., Silbermann B., Bary M., Girard PM., Lacombe K. 2014
Hepatitis B screening: who to target? A French sexually transmitted infection clinic experience. Spenatto N., Boulinguez S., Mularczyk M., Molinier L., Bureau C., Saune K., Viraben R. 2013
Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. Wolffram I., Petroff D., Bätz O., Jedrysiak K., Kramer J., Tenckhoff H., Berg T., Wiegand J. 2015
Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Bozkaya H., Yurdaydin C., Idilman R., Tüzün A., Cinar K., Erkan O., Bozdayi AM., Erden E., Uzun Y., Cetinkaya H., Uzunalimoglu O. 2005
Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Chan HL., Wang H., Niu J., Chim AM., Sung JJ. 2007
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. Chang TT., Chao YC., Gorbakov VV., Han KH., Gish RG., de Man R., Cheinquer H., Bessone F., Brett-Smith H., Tamez R. 2009
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Chang TT., Gish RG., de Man R., Gadano A., Sollano J., Chao YC., Lok AS., Han KH., Goodman Z., Zhu J., Cross A., DeHertogh D., Wilber R., Colonno R., Apelian D. 2006
Lamivudine as initial treatment for chronic hepatitis B in the United States. Dienstag JL., Schiff ER., Wright TL., Perrillo RP., Hann HW., Goodman Z., Crowther L., Condreay LD., Woessner M., Rubin M., Brown NA. 1999
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gish RG., Lok AS., Chang TT., de Man RA., Gadano A., Sollano J., Han KH., Chao YC., Lee SD., Harris M., Yang J., Colonno R., Brett-Smith H. 2007
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. Hadziyannis SJ., Tassopoulos NC., Heathcote EJ., Chang TT., Kitis G., Rizzetto M., Marcellin P., Lim SG., Goodman Z., Wulfsohn MS., Xiong S., Fry J., Brosgart CL. 2003
Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Hoang JK., Yang HI., Le A., Nguyen NH., Lin D., Vu VD., Chaung K., Nguyen V., Trinh HN., Li J., Zhang JQ., Chen CJ., Nguyen MH. 2016
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hosaka T., Suzuki F., Kobayashi M., Seko Y., Kawamura Y., Sezaki H., Akuta N., Suzuki Y., Saitoh S., Arase Y., Ikeda K., Kobayashi M., Kumada H. 2013
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. Hou JL., Gao ZL., Xie Q., Zhang JM., Sheng JF., Cheng J., Chen CW., Mao Q., Zhao W., Ren H., Tan DM., Niu JQ., Chen SJ., Pan C., Tang H., Wang H., Mao YM., Jia JD., Ning Q., Xu M., Wu SM., Li J., Zhang XX., Ji Y., Dong J., Li J. 2015
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Lai CL., Chien RN., Leung NW., Chang TT., Guan R., Tai DI., Ng KY., Wu PC., Dent JC., Barber J., Stephenson SL., Gray DF. 1998
Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Lai CL., Ching CK., Tung AK., Li E., Young J., Hill A., Wong BC., Dent J., Wu PC. 1997
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Lai CL., Shouval D., Lok AS., Chang TT., Cheinquer H., Goodman Z., DeHertogh D., Wilber R., Zink RC., Cross A., Colonno R., Fernandes L. 2006
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Lai CL., Rosmawati M., Lao J., Van Vlierberghe H., Anderson FH., Thomas N., Dehertogh D. 2002
A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Lampertico P., Del Ninno E., Manzin A., Donato MF., Rumi MG., Lunghi G., Morabito A., Clementi M., Colombo M. 1997
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Lau GK., Piratvisuth T., Luo KX., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried MW., Chow WC., Paik SW., Chang WY., Berg T., Flisiak R., McCloud P., Pluck N. 2005
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Lee KS., Kweon YO., Um SH., Kim BH., Lim YS., Paik SW., Heo J., Lee HJ., Kim DJ., Kim TH., Lee YS., Byun KS., Kim D., Lee MS., Yu K., Suh DJ. 2017
Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B. Lee TY., Hsu YC., Yu SH., Lin JT., Wu MS., Wu CY. 2018
Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. Liaw YF., Lin SM., Chen TJ., Chien RN., Sheen IS., Chu CM. 1994
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Lin SM., Sheen IS., Chien RN., Chu CM., Liaw YF. 1999
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P., Chang TT., Lim SG., Tong MJ., Sievert W., Shiffman ML., Jeffers L., Goodman Z., Wulfsohn MS., Xiong S., Fry J., Brosgart CL. 2003
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P., Heathcote EJ., Buti M., Gane E., de Man RA., Krastev Z., Germanidis G., Lee SS., Flisiak R., Kaita K., Manns M., Kotzev I., Tchernev K., Buggisch P., Weilert F., Kurdas OO., Shiffman ML., Trinh H., Washington MK., Sorbel J., Anderson J., Snow-Lampart A., Mondou E., Quinn J., Rousseau F. 2008
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Matsumoto A., Tanaka E., Rokuhara A., Kiyosawa K., Kumada H., Omata M., Okita K., Hayashi N., Okanoue T., Iino S., Tanikawa K. 2005
Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Mazzella G., Saracco G., Festi D., Rosina F., Marchetto S., Jaboli F., Sostegni R., Pezzoli A., Azzaroli F., Cancellieri C., Montagnani M., Roda E., Rizzetto M. 1999
Treatment of chronic hepatitis B with interferon alfa-2b. Müller R., Baumgarten R., Markus R., Schulz M., Wittenberg H., Hintsche-Kilger B., Fengler JD., Von Wussow P., Meisel H., Klein H. 1990
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. Realdi G., Fattovich G., Pastore G., Caredda F., Noventa F., Santantonio T., Moroni M., Criscuolo D., Maladorno D., Rugge M. 1990
A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. Ren FY., Piao DM., Piao XX. 2007
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Suh DJ., Um SH., Herrmann E., Kim JH., Lee YS., Lee HJ., Lee MS., Lee YJ., Bao W., Lopez P., Lee HC., Avila C., Zeuzem S. 2010
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Tassopoulos NC., Volpes R., Pastore G., Heathcote J., Buti M., Goldin RD., Hawley S., Barber J., Condreay L., Gray DF. 1999
Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. Thomas HC., Lok AS., Carreño V., Farrell G., Tanno H., Perez V., Dusheiko GM., Cooksley G., Ryff JC. 1994
Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study. Tseng KC., Chen CY., Tsai HW., Chang TT., Chuang WL., Hsu PI., Liu WC., Cheng PN. 2014
Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study. Wang JP., Kao FY., Wu CY., Hung YP., Chao Y., Chou YJ., Li CP. 2015
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. Wei MT., Le AK., Chang MS., Hsu H., Nguyen P., Zhang JQ., Wong C., Wong C., Cheung R., Nguyen MH. 2019
Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy. Wen Z., Zhang H., Zhang M., Tan D., Li Q., Zhang H., Wu P., Deng L. 2014
Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Wu CY., Lin JT., Ho HJ., Su CW., Lee TY., Wang SY., Wu C., Wu JC. 2014
A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels. Yalçin K., Değertekin H., Kokoğlu OF., Ayaz C. 2004
Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Yao G., Chen C., Lu W., Ren H., Tan D., Wang Y., Xu D., Jiang Z., Liu J., Xu D., Macdonald L. 2007
A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Yao G., Wang B., Cui Z., Yao J., Zeng M. 1999
Management of hepatitis B in China. Yao GB. 2000
A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. Yao GB., Zhu M., Cui ZY., Wang BE., Yao JL., Zeng MD. 2009
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Zheng MH., Shi KQ., Dai ZJ., Ye C., Chen YP. 2010
Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece. Baltayiannis G., Katsanos K., Karayiannis P., Tsianos EV. 2006
Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Gordon SC., Lamerato LE., Rupp LB., Li J., Holmberg SD., Moorman AC., Spradling PR., Teshale EH., Vijayadeva V., Boscarino JA., Henkle EM., Oja-Tebbe N., Lu M. 2014
Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications. Hui CK., Leung N., Shek WH., Zhang HY., Luk JM., Poon RT., Lo CM., Fan ST., Lau GK. -- Not Found --
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Lau DT., Everhart J., Kleiner DE., Park Y., Vergalla J., Schmid P., Hoofnagle JH. 1997
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. Lin SM., Yu ML., Lee CM., Chien RN., Sheen IS., Chu CM., Liaw YF. 2007
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. Niederau C., Heintges T., Lange S., Goldmann G., Niederau CM., Mohr L., Häussinger D. 1996
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. Papatheodoridis GV., Manesis E., Hadziyannis SJ. 2001
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Papatheodoridis GV., Manolakopoulos S., Touloumi G., Vourli G., Raptopoulou-Gigi M., Vafiadis-Zoumbouli I., Vasiliadis T., Mimidis K., Gogos C., Ketikoglou I., Manesis EK. 2011




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/